Cantor Fitzgerald Weighs in on Zai Lab FY2025 Earnings
Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Zai Lab in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen forecasts that the ...
Hosted on MSN19h
FDA grants ODD status to Zai Lab’s lung cancer treatment
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Zai Lab’s delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), ZL-1310, for small cell lung cancer (SCLC).
Vertex Pharmaceuticals (VRTX) Receives a Buy from Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...
Exploring Three High Growth Tech Stocks In The United States
The United States market has shown robust performance recently, climbing 3.0% in the last week and achieving a 25% increase over the past year, with earnings expected to grow by 15% annually. In this ...
FY2025 Earnings Estimate for UNH Issued By Cantor Fitzgerald
Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for UnitedHealth Group in a ...